CimCure develops cancer vaccines utilizing its proprietary Immune-Boost (iBoost) technology, which fuses a foreign protein to a protein on tumor-associated blood vessels, prompting the immune system to produce antibodies that target and destroy these vessels. This approach effectively halts tumor growth and eliminates cancer without inducing resistance to the therapy.
Funding
$5.3M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
PVFounders
Product
Problem
Current cancer treatments often fail to eradicate tumors completely or lead to the development of resistance, necessitating new therapeutic approaches. Many existing therapies do not specifically target the tumor microenvironment, leading to off-target effects and limiting their efficacy.
Solution
CimCure is developing cancer vaccines that target and destroy the tumor's blood vessel network, effectively halting tumor growth and spread. The company's proprietary Immune-Boost (iBoost) technology fuses a foreign protein to a protein found on tumor-associated blood vessels. This prompts the patient's immune system to produce antibodies that specifically target and destroy these vessels, cutting off the tumor's nutrient supply. This approach aims to eliminate cancer without inducing resistance, offering a potential solution for solid tumors at all stages.
Target Audience
The primary target audience includes cancer patients with solid tumors, as well as oncologists and researchers seeking novel immunotherapeutic approaches.
Features
- iBoost technology platform for generating targeted cancer vaccines
- Vaccine targets tumor-associated blood vessels to disrupt the tumor microenvironment
- Induces an immune response to destroy tumor vasculature
- CVx1, a lead product, has demonstrated safety and efficacy in preclinical studies and in client-owned dogs with spontaneous bladder cancer
- Granted patents for iBoost technology in both the US and Europe
- GMP production capabilities for clinical trial material